Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nuvectis Pharma Inc NVCT

Healthcare Biotechnology
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also... see more

Current News (NDAQ:NVCT)

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

GlobeNewswire December 17, 2025

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

GlobeNewswire November 25, 2025

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

GlobeNewswire November 4, 2025

Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

GlobeNewswire November 4, 2025

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 27, 2025

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 16, 2025

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

GlobeNewswire September 25, 2025

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 4, 2025

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

GlobeNewswire August 11, 2025
View More News ››

Opinion & Analysis (NDAQ:NVCT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NVCT)

Be the first to post on this bullboard.

Almonty Industries Inc.

Almonty Industries Inc.

Almonty Industries Inc. engages in mining, processing, and shipping of tungsten concentrate. The company explores for tin and ...
View More »

Podcasts